JP7602546B2 - Ｈｄａｃ６阻害剤として有用な２－イソインドール－１，３，４－オキサジアゾール誘導体 - Google Patents
Ｈｄａｃ６阻害剤として有用な２－イソインドール－１，３，４－オキサジアゾール誘導体 Download PDFInfo
- Publication number
- JP7602546B2 JP7602546B2 JP2022545275A JP2022545275A JP7602546B2 JP 7602546 B2 JP7602546 B2 JP 7602546B2 JP 2022545275 A JP2022545275 A JP 2022545275A JP 2022545275 A JP2022545275 A JP 2022545275A JP 7602546 B2 JP7602546 B2 JP 7602546B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- disease
- halogen atoms
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019177815 | 2019-09-27 | ||
| JP2019177815 | 2019-09-27 | ||
| PCT/JP2020/037386 WO2021060567A1 (en) | 2019-09-27 | 2020-09-24 | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022552444A JP2022552444A (ja) | 2022-12-15 |
| JP2022552444A5 JP2022552444A5 (https=) | 2023-10-02 |
| JP7602546B2 true JP7602546B2 (ja) | 2024-12-18 |
Family
ID=73040188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545275A Active JP7602546B2 (ja) | 2019-09-27 | 2020-09-24 | Ｈｄａｃ６阻害剤として有用な２－イソインドール－１，３，４－オキサジアゾール誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11453661B2 (https=) |
| EP (1) | EP4034536A1 (https=) |
| JP (1) | JP7602546B2 (https=) |
| KR (1) | KR20220070465A (https=) |
| CN (1) | CN114846012B (https=) |
| AR (1) | AR120040A1 (https=) |
| AU (1) | AU2020353984B2 (https=) |
| BR (1) | BR112022005595A2 (https=) |
| CA (1) | CA3156060A1 (https=) |
| CL (1) | CL2022000763A1 (https=) |
| CO (1) | CO2022005059A2 (https=) |
| EC (1) | ECSP22026524A (https=) |
| IL (1) | IL291413B2 (https=) |
| MX (1) | MX2022003490A (https=) |
| PE (1) | PE20220711A1 (https=) |
| PH (1) | PH12022550748A1 (https=) |
| TW (1) | TWI882012B (https=) |
| WO (1) | WO2021060567A1 (https=) |
| ZA (1) | ZA202204666B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| WO2021060567A1 (en) * | 2019-09-27 | 2021-04-01 | Takeda Pharmaceutical Company Limited | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors |
| MX2022007376A (es) | 2019-12-20 | 2022-09-02 | Tenaya Therapeutics Inc | Fluoroalqull-oxadiazoles y sus usos. |
| IL307883A (en) | 2021-04-23 | 2023-12-01 | Tenaya Therapeutics Inc | HDAC6 inhibitors for use in the treatment of dilated myocardial disease |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| CN114166824B (zh) * | 2021-12-08 | 2024-01-23 | 桂林医学院 | 一种辅剂示踪分析保健品中药物含量的方法 |
| TW202345813A (zh) | 2022-04-08 | 2023-12-01 | 美商艾科尼佐療法股份有限公司 | 㗁二唑ｈｄａｃ６抑制劑及其用途 |
| TW202400147A (zh) * | 2022-04-15 | 2024-01-01 | 大陸商勤浩醫藥(蘇州)有限公司 | 噁二唑化合物、包含其的藥物組合物及其用途 |
| AU2024240637A1 (en) * | 2023-03-21 | 2025-09-18 | Vivozon,Inc. | Double regulator for mglur5 and hdac6 and use thereof |
| TW202513061A (zh) * | 2023-09-28 | 2025-04-01 | 大陸商勤浩醫藥(蘇州)有限公司 | 一種hdac6抑制劑的結晶形式及其製備方法 |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
| CN119823019A (zh) * | 2025-01-06 | 2025-04-15 | 沈阳药科大学 | 一种具有治疗特发性肺纤维化作用的吲哚类化合物及其制备方法和应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017004170A1 (en) | 2015-06-30 | 2017-01-05 | Wm. Wrigley Jr. Company | Package for confectionary products and method for forming same |
| WO2017014321A1 (en) | 2015-07-17 | 2017-01-26 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as hdac inhibitors |
| EP3327019A1 (en) | 2015-07-17 | 2018-05-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP2018521110A (ja) | 2015-07-27 | 2018-08-02 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールアミド誘導体化合物及びこれを含有する薬剤学的組成物， |
| JP2018521092A (ja) | 2015-07-27 | 2018-08-02 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールスルファミド誘導体化合物及びこれを含有する薬剤学的組成物（１，３，４−Ｏｘａｄｉａｚｏｌｅ Ｓｕｌｆａｍｉｄｅ Ｄｅｒｉｖａｔｉｖｅ Ｃｏｍｐｏｕｎｄｓ ａｓ Ｈｉｓｔｏｎｅ Ｄｅａｃｅｔｙｌａｓｅ ６ Ｉｎｈｉｂｉｔｏｒ， ａｎｄ ｔｈｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐｏｓｉｔｉｏｎ Ｃｏｍｐｒｉｓｉｎｇ ｔｈｅ ｓａｍｅ） |
| WO2019027054A1 (en) | 2017-07-31 | 2019-02-07 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| JP2021532130A (ja) | 2018-07-26 | 2021-11-25 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物およびそれを含む薬剤学的組成物 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US20040142859A1 (en) | 2002-05-02 | 2004-07-22 | Steffan Joan S. | Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
| EP1390491B1 (en) | 2001-05-02 | 2008-07-16 | The Regents of the University of California | Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors |
| US20050227915A1 (en) | 2001-05-02 | 2005-10-13 | Steffan Joan S | Methods and reagents for treating neurodegenerative diseases and motor deficit disorders |
| AU2002340253C1 (en) | 2001-10-16 | 2011-03-31 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| CN101259120B (zh) | 2002-03-04 | 2012-07-04 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途 |
| US20050009030A1 (en) | 2002-03-26 | 2005-01-13 | Fabien Schweighoffer | Histone deacetylase: novel molecular target of neurotoxicity |
| AU2003226014A1 (en) | 2002-03-28 | 2003-10-13 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
| ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US20060018921A1 (en) | 2004-07-16 | 2006-01-26 | Baylor College Of Medicine | Histone deacetylase inhibitors and cognitive applications |
| GT200500321A (es) | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
| CN101056632B (zh) * | 2004-11-09 | 2011-12-07 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US8999289B2 (en) | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| US20100004156A1 (en) | 2005-07-27 | 2010-01-07 | Shalesh Kaushal | Small Compounds That Correct Protein Misfolding and Uses Thereof |
| EP1937236A2 (en) | 2005-09-07 | 2008-07-02 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
| WO2007049262A1 (en) | 2005-10-27 | 2007-05-03 | Berand Limited | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders |
| WO2007055941A2 (en) | 2005-11-03 | 2007-05-18 | Merck & Co., Inc. | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
| US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
| GB0612273D0 (en) | 2006-06-21 | 2006-08-02 | Friedrich Miescher Inst For Bi | Prevention of muscle atrophy |
| US8088951B2 (en) | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
| WO2008073733A1 (en) | 2006-12-08 | 2008-06-19 | Kalypsys, Inc. | Salts of inhibitors of histone deacetylase for the treatment of disease |
| AU2007333799A1 (en) | 2006-12-15 | 2008-06-26 | Novartis Ag | Heterocycle compounds and methods of use thereof |
| WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| WO2009027349A2 (en) | 2007-08-24 | 2009-03-05 | Oryzon Genomics Sa | Treatment and prevention of neurodegenerative diseases |
| US20090136461A1 (en) | 2007-11-28 | 2009-05-28 | Moon Suk Kim | Neuronal differentiation method of adult stem cells using small molecules |
| AU2013203735A1 (en) * | 2007-12-04 | 2013-05-02 | F. Hoffmann-La Roche Ag | Isoxazolo-pyridine derivatives |
| BR112012015129A2 (pt) * | 2009-12-22 | 2019-09-24 | Celgene Corp | "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio" |
| US8981084B2 (en) | 2010-01-13 | 2015-03-17 | Tempero Pharmaceuticals, Inc. | Oxadiazole HDAC inhibitors |
| AU2011205283B2 (en) | 2010-01-13 | 2014-07-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| ES2647368T3 (es) | 2010-10-08 | 2017-12-21 | Vib Vzw | Inhibidores de HDAC para tratar la enfermedad de Charcot-Marie-Tooth |
| EP2632900A2 (en) | 2010-10-28 | 2013-09-04 | Merck Sharp & Dohme Corp. | Caprolactam mglur5 receptor modulators |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US9540395B2 (en) | 2011-02-28 | 2017-01-10 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| CA2834548C (en) | 2011-04-28 | 2021-06-01 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| US20140235649A1 (en) | 2011-05-24 | 2014-08-21 | Lixte Biotechnology, Inc. | Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function |
| WO2013006408A1 (en) | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EA201490228A1 (ru) | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| WO2013009827A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009830A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| EP2734500A4 (en) | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066831A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| BR112014012815A8 (pt) | 2011-11-28 | 2017-06-20 | Novartis Ag | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença |
| US9480673B2 (en) | 2012-03-29 | 2016-11-01 | The Regents Of The University Of Colorado, A Body Corporate | Composition and method for treating neurodegenerative disease |
| EP2841067A4 (en) | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
| WO2014006114A1 (en) | 2012-07-05 | 2014-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
| CN104894060B (zh) | 2014-03-03 | 2018-11-06 | 中国科学院上海生命科学研究院 | 诱导体细胞转分化为神经干细胞的方法及其应用 |
| JP6392888B2 (ja) * | 2014-03-12 | 2018-09-19 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としての新規化合物およびこれを含む薬剤学的組成物 |
| US10081624B2 (en) | 2014-08-26 | 2018-09-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JPWO2016039398A1 (ja) | 2014-09-09 | 2017-06-15 | 国立大学法人大阪大学 | 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物 |
| PL3292116T3 (pl) | 2015-02-02 | 2022-02-21 | Valo Health, Inc. | 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac |
| PL3328843T3 (pl) | 2015-07-27 | 2023-02-27 | Chong Kun Dang Pharmaceutical Corp. | Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca |
| JP6491393B2 (ja) | 2015-08-04 | 2019-03-27 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物 |
| WO2017033946A1 (ja) | 2015-08-25 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6697074B2 (ja) * | 2015-10-12 | 2020-05-20 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としてのオキサジアゾールアミン誘導体化合物及びこれを含有する薬剤学的組成物 |
| WO2017222952A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| US20180016314A1 (en) | 2016-07-12 | 2018-01-18 | Children's Hospital Medical Center | Treatment of disease via transcription factor modulation |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| WO2018215597A1 (en) | 2017-05-24 | 2018-11-29 | Orphazyme A/S | Heat shock protein inducers and frontotemporal disorders |
| US11458122B2 (en) | 2017-08-09 | 2022-10-04 | Children's Hospital Medical Center | Methods for treating diseases and nerve injuries |
| US20200216563A1 (en) | 2017-08-10 | 2020-07-09 | Friedrich Miescher Institute For Biomedical Research | Hdac6 and protein aggregation |
| JP6910984B2 (ja) | 2018-03-30 | 2021-07-28 | 株式会社ホンダアクセス | 脱出ハンマー収容具 |
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| US12084436B2 (en) | 2019-01-30 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2021060567A1 (en) * | 2019-09-27 | 2021-04-01 | Takeda Pharmaceutical Company Limited | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors |
-
2020
- 2020-09-24 WO PCT/JP2020/037386 patent/WO2021060567A1/en not_active Ceased
- 2020-09-24 AR ARP200102652A patent/AR120040A1/es unknown
- 2020-09-24 IL IL291413A patent/IL291413B2/en unknown
- 2020-09-24 TW TW109133124A patent/TWI882012B/zh active
- 2020-09-24 PE PE2022000460A patent/PE20220711A1/es unknown
- 2020-09-24 MX MX2022003490A patent/MX2022003490A/es unknown
- 2020-09-24 CN CN202080068097.3A patent/CN114846012B/zh active Active
- 2020-09-24 EP EP20800345.9A patent/EP4034536A1/en active Pending
- 2020-09-24 CA CA3156060A patent/CA3156060A1/en active Pending
- 2020-09-24 AU AU2020353984A patent/AU2020353984B2/en active Active
- 2020-09-24 BR BR112022005595A patent/BR112022005595A2/pt unknown
- 2020-09-24 JP JP2022545275A patent/JP7602546B2/ja active Active
- 2020-09-24 US US17/030,504 patent/US11453661B2/en active Active
- 2020-09-24 PH PH1/2022/550748A patent/PH12022550748A1/en unknown
- 2020-09-24 KR KR1020227012924A patent/KR20220070465A/ko active Pending
-
2022
- 2022-03-25 CL CL2022000763A patent/CL2022000763A1/es unknown
- 2022-04-04 EC ECSENADI202226524A patent/ECSP22026524A/es unknown
- 2022-04-22 CO CONC2022/0005059A patent/CO2022005059A2/es unknown
- 2022-04-26 ZA ZA2022/04666A patent/ZA202204666B/en unknown
- 2022-09-26 US US17/952,546 patent/US11958845B2/en active Active
-
2024
- 2024-04-15 US US18/635,839 patent/US12384770B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017004170A1 (en) | 2015-06-30 | 2017-01-05 | Wm. Wrigley Jr. Company | Package for confectionary products and method for forming same |
| WO2017014321A1 (en) | 2015-07-17 | 2017-01-26 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as hdac inhibitors |
| EP3327019A1 (en) | 2015-07-17 | 2018-05-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP2018524378A (ja) | 2015-07-17 | 2018-08-30 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2018521110A (ja) | 2015-07-27 | 2018-08-02 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールアミド誘導体化合物及びこれを含有する薬剤学的組成物， |
| JP2018521092A (ja) | 2015-07-27 | 2018-08-02 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールスルファミド誘導体化合物及びこれを含有する薬剤学的組成物（１，３，４−Ｏｘａｄｉａｚｏｌｅ Ｓｕｌｆａｍｉｄｅ Ｄｅｒｉｖａｔｉｖｅ Ｃｏｍｐｏｕｎｄｓ ａｓ Ｈｉｓｔｏｎｅ Ｄｅａｃｅｔｙｌａｓｅ ６ Ｉｎｈｉｂｉｔｏｒ， ａｎｄ ｔｈｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐｏｓｉｔｉｏｎ Ｃｏｍｐｒｉｓｉｎｇ ｔｈｅ ｓａｍｅ） |
| WO2019027054A1 (en) | 2017-07-31 | 2019-02-07 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| JP2021532130A (ja) | 2018-07-26 | 2021-11-25 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物およびそれを含む薬剤学的組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114846012A (zh) | 2022-08-02 |
| US11958845B2 (en) | 2024-04-16 |
| TWI882012B (zh) | 2025-05-01 |
| BR112022005595A2 (pt) | 2022-07-19 |
| CL2022000763A1 (es) | 2023-01-20 |
| PE20220711A1 (es) | 2022-05-04 |
| AU2020353984A1 (en) | 2022-04-21 |
| IL291413B2 (en) | 2025-03-01 |
| AU2020353984B2 (en) | 2025-09-25 |
| IL291413A (en) | 2022-05-01 |
| JP2022552444A (ja) | 2022-12-15 |
| US20230183227A1 (en) | 2023-06-15 |
| ZA202204666B (en) | 2023-11-29 |
| US20210094944A1 (en) | 2021-04-01 |
| TW202126643A (zh) | 2021-07-16 |
| PH12022550748A1 (en) | 2023-11-20 |
| AU2020353984A2 (en) | 2022-08-04 |
| KR20220070465A (ko) | 2022-05-31 |
| CA3156060A1 (en) | 2021-04-01 |
| CO2022005059A2 (es) | 2022-07-08 |
| US12384770B2 (en) | 2025-08-12 |
| EP4034536A1 (en) | 2022-08-03 |
| IL291413B1 (en) | 2024-11-01 |
| WO2021060567A1 (en) | 2021-04-01 |
| MX2022003490A (es) | 2022-04-25 |
| US20240343721A1 (en) | 2024-10-17 |
| AR120040A1 (es) | 2022-01-26 |
| US11453661B2 (en) | 2022-09-27 |
| CN114846012B (zh) | 2024-01-26 |
| ECSP22026524A (es) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7602546B2 (ja) | Ｈｄａｃ６阻害剤として有用な２－イソインドール－１，３，４－オキサジアゾール誘導体 | |
| JP7470058B2 (ja) | 複素環化合物 | |
| JP7135007B2 (ja) | 複素環化合物 | |
| US12378256B2 (en) | Heterocyclic compound | |
| JPWO2019022179A1 (ja) | 複素環化合物 | |
| CN112752760B (zh) | 杂环化合物 | |
| JPWO2019070043A1 (ja) | 複素環化合物 | |
| JP7250687B2 (ja) | 複素環化合物 | |
| KR102658949B1 (ko) | 헤테로시클릭 화합물 | |
| EA045216B1 (ru) | Производные 2-изоиндол-1,3,4-оксадиазола, применимые в качестве ингибиторов hdac6 | |
| JP7443238B2 (ja) | 複素環化合物 | |
| JPWO2020067457A1 (ja) | 縮合環化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230922 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240903 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240911 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241206 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7602546 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |